MiniMed 780G System Real World Evidence User Manual
- June 15, 2024
- MiniMed
Table of Contents
- 780G System Real World Evidence
- MiniMed™ 780G system reduces the gap in glycaemic control post AHCL
- Users sustained their outcomes over the 12 months observation period
- Recommended optimal settings* for better outcomes 1
- References
- Read User Manual Online (PDF format)
- Download This Manual (PDF format)
**03. Delivers proven clinical outcomes in a wide T1D population*
MiniMed™ 780G system real-world evidence 1**
780G System Real World Evidence
Scope of the analysis and methods
Scope of the analysis:
- Uploaded on CareLink™ Personal from 27 August 2020 to 02 December 2022
- By 61,481 users or caregivers who provided their consent for their data to be aggregated
- From countries where local data privacy regulation permits data analysis
Methodology:
3 cohorts were analyzed for overall population and per user self-reported age
≤15 or >15 years
Post-AHCL cohort
All users with ≥10 days of SG data after initiating AHCL (N=61,481)
Pre- and post-AHCL cohort
All users with ≥10 days of SG data before and after initiating AHCL
(N=15,395). The analyses are adjusted for baseline TIR (pre-AHCL initiation).
This is the cohort used for statistical analysis
Longitudinal cohort
All users with ≥10 days of SG data in each of the first 12 months after
initiating AHCL (N=11,617)
The MiniMed™ 780G insulin pump is indicated for
use by patients aged 7-80 years with Type 1 diabetes.
1. Medtronic data on file: MiniMed ™ 780G data uploaded voluntarily by 61,481
users in EMEA to CareLink™
Personal, from August 2020 to dec 2022.
Post-AHCL cohort:
61,481
users
Achieving glycaemic targets
*The MiniMed™ 780G insulin pump is indicated
for use by patients aged 7-80 years with Type 1 diabetes.
** Glucose Management Indicator (GMI) based on reported mean glucose values.
Calculated using JAEB https://www.jaeb.org/gmi/.
- Medtronic data on file: MiniMed ™ 780G data uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to dec 2022..
- Battelino T, et al. Diabetes Care 2019; 42: 1593-1603.
Pre- and Post-AHCL cohort:
15,395
Users improved clinical outcomes vs Pre-SmartGuard™ initiation
*The MiniMed™ 780G insulin pump is indicated for use by patients
aged 7-80 years with Type 1 diabetes.
** Glucose Management Indicator (GMI) based on reported mean glucose values.
Calculated using JAEB https://www.jaeb.org/gmi/.
MiniMed™ 780G system reduces the gap in glycaemic control post AHCL
initiation
- Medtronic data on file: MiniMed ™ 780G data uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to dec 2022.
Between paediatrics and adults 1
The MiniMed™ 780G insulin pump is indicated
for use by patients aged 7-80 years with Type 1 diabetes.
Glucose Management Indicator (GMI) based on reported mean glucose values.
Calculated using JAEB https://www.jaeb.org/gmi/.
Some users not included in the analysis because of age not shared.
- Medtronic data on file: MiniMed ™ 780G data uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to dec 2022..
Users sustained their outcomes over the 12 months observation period
MiniMed™ 780G system real-world outcomes 1
- Medtronic data on file: MiniMed ™ 780G data uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to dec 2022..
P value nor sifnificant
Recommended optimal settings* for better outcomes 1
In the real-world evidence
- Medtronic data on file: MiniMed ™ 780G data uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to dec 2022.
*Users with recommended optimal settings are the ones using the combination of glucose target setting at 100 mg/dL and Active Insulin Time (AIT) at 2 hours for at least 95% of the time.